Cost-utility analysis of teriflunomide in naïve vs. previously treated patients with relapsing–remitting multiple sclerosis in Italy

BACKGROUND: Multiple sclerosis (MS) accounts for 176 cases per 100,000 inhabitants (female/male ratio = 2:1) in Italy. For most of the patients (67%), the disease course is relapsing–remitting MS (RRMS). OBJECTIVE: To compare the costs and quality-adjusted life years (QALYs) of teriflunomide in RRMS...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazzaro, Carlo, Bergamaschi, Roberto, Zaffaroni, Mauro, Totaro, Rocco, Paolicelli, Damiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349140/
https://www.ncbi.nlm.nih.gov/pubmed/35420360
http://dx.doi.org/10.1007/s10072-022-06022-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349140/
https://www.ncbi.nlm.nih.gov/pubmed/35420360
http://dx.doi.org/10.1007/s10072-022-06022-x

Ejemplares similares